| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1474-4422(15)00186-6 |
| P698 | PubMed publication ID | 26376970 |
| P50 | author | Mattia Volta | Q58567856 |
| Matthew J. Farrer | Q37380292 | ||
| P2093 | author name string | Austen J Milnerwood | |
| P2860 | cites work | Retromer mediates a discrete route of local membrane delivery to dendrites | Q39830330 |
| A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease | Q40254829 | ||
| Living on the edge with too many mouths to feed: why dopamine neurons die. | Q41732813 | ||
| Synaptic function is modulated by LRRK2 and glutamate release is increased in cortical neurons of G2019S LRRK2 knock-in mice. | Q41978493 | ||
| A critical evaluation of the Braak staging scheme for Parkinson's disease. | Q42260364 | ||
| LRRK2 overexpression alters glutamatergic presynaptic plasticity, striatal dopamine tone, postsynaptic signal transduction, motor activity and memory | Q42467623 | ||
| Dopamine turnover increases in asymptomatic LRRK2 mutations carriers | Q42861721 | ||
| Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice | Q44430640 | ||
| A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease | Q44571920 | ||
| Comparative study of Parkinson's disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism | Q44637181 | ||
| Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease | Q44769508 | ||
| Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum. | Q46162532 | ||
| Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease | Q48168351 | ||
| EIF4G1 is neither a strong nor a common risk factor for Parkinson's disease: evidence from large European cohorts | Q48256432 | ||
| 100 years of Lewy pathology | Q48278741 | ||
| Retromer-dependent neurotransmitter receptor trafficking to synapses is altered by the Parkinson's disease VPS35 mutation p.D620N. | Q48449821 | ||
| Disease penetrance of late-onset parkinsonism: a meta-analysis | Q48480120 | ||
| Toward a redefinition of Parkinson's disease | Q83264509 | ||
| Exosomes: vehicles for the transfer of toxic proteins associated with neurodegenerative diseases? | Q21129257 | ||
| GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1 | Q21144926 | ||
| Imaging Approaches to Parkinson Disease | Q22241268 | ||
| Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice | Q24293070 | ||
| Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson's disease | Q24294458 | ||
| LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex | Q24298891 | ||
| SNX27 mediates retromer tubule entry and endosome-to-plasma membrane trafficking of signalling receptors | Q24304190 | ||
| ArfGAP1 Is a GTPase Activating Protein for LRRK2: Reciprocal Regulation of ArfGAP1 by LRRK2 | Q24307742 | ||
| A direct interaction between leucine-rich repeat kinase 2 and specific β-tubulin isoforms regulates tubulin acetylation | Q24310126 | ||
| RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk | Q24315688 | ||
| Interplay of LRRK2 with chaperone-mediated autophagy | Q24322747 | ||
| LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity | Q24323196 | ||
| A global analysis of SNX27–retromer assembly and cargo specificity reveals a function in glucose and metal ion transport | Q24337927 | ||
| Leucine-rich repeat kinase 2 regulates tau phosphorylation through direct activation of glycogen synthase kinase-3β | Q24338942 | ||
| RME-8 coordinates the activity of the WASH complex with the function of the retromer SNX dimer to control endosomal tubulation | Q24339406 | ||
| Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro | Q24629968 | ||
| A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease | Q24633417 | ||
| Synaptic vesicle exocytosis | Q26269869 | ||
| The retromer complex - endosomal protein recycling and beyond | Q26866457 | ||
| Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice | Q27308060 | ||
| Mutation in the alpha-synuclein gene identified in families with Parkinson's disease | Q27860459 | ||
| alpha-Synuclein locus triplication causes Parkinson's disease | Q27860533 | ||
| CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease: a genome-wide linkage and sequencing study | Q28114901 | ||
| Parkinson's disease genes VPS35 and EIF4G1 interact genetically and converge on α-synuclein | Q28117589 | ||
| Staging of brain pathology related to sporadic Parkinson's disease | Q28131702 | ||
| Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology | Q28131833 | ||
| Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease | Q28244731 | ||
| Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases | Q28257057 | ||
| Metabotropic glutamate receptors in the basal ganglia motor circuit | Q28280931 | ||
| Retromer-mediated endosomal protein sorting: all WASHed up! | Q28291654 | ||
| 'Rejuvenation' protects neurons in mouse models of Parkinson's disease | Q28305585 | ||
| αβγ-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction | Q28506296 | ||
| Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S | Q28589899 | ||
| Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system | Q28594502 | ||
| DNAJC13 mutations in Parkinson disease | Q28658355 | ||
| R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. | Q30483115 | ||
| LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors | Q30524899 | ||
| The location and trafficking routes of the neuronal retromer and its role in amyloid precursor protein transport | Q30537229 | ||
| Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia | Q33340612 | ||
| Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. | Q33594388 | ||
| Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study | Q33668068 | ||
| Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease | Q33754793 | ||
| Lrrk2 localization in the primate basal ganglia and thalamus: a light and electron microscopic analysis in monkeys | Q34005501 | ||
| Monomeric Synucleins Generate Membrane Curvature | Q34313934 | ||
| Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions. | Q34359440 | ||
| Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating “clinical proof-of-concept” for AAV-neurturin (CERE-120) in Parkinson's disease | Q38038438 | ||
| Lysosome-dependent pathways as a unifying theme in Parkinson's disease. | Q38038561 | ||
| LRRK2 and vesicle trafficking | Q38044441 | ||
| Drug treatments for the neuropsychiatric complications of Parkinson's disease | Q38067142 | ||
| Neurobiology of cognitive impairment in Parkinson’s disease | Q38067143 | ||
| α-Synuclein and mitochondrial dysfunction in Parkinson's disease | Q38077665 | ||
| Neuronal vulnerability, pathogenesis, and Parkinson's disease | Q38099288 | ||
| Integrating pathways of Parkinson's disease in a molecular interaction map. | Q38119873 | ||
| Advances in the genetics of Parkinson disease | Q38121773 | ||
| Synchronized neural oscillations and the pathophysiology of Parkinson's disease. | Q38154792 | ||
| Do studies on cortical plasticity provide a rationale for using non-invasive brain stimulation as a treatment for Parkinson's disease patients? | Q38162220 | ||
| Modeling Lewy pathology propagation in Parkinson's disease | Q38164894 | ||
| Novel insights into the neurobiology underlying LRRK2-linked Parkinson's disease. | Q38215066 | ||
| The association between the LRRK2 G2385R variant and the risk of Parkinson's disease: a meta-analysis based on 23 case-control studies | Q38229792 | ||
| Genetics and genomics of Parkinson's disease | Q38233866 | ||
| Direct and indirect pathways of basal ganglia: a critical reappraisal | Q38234309 | ||
| The Vps35 D620N mutation linked to Parkinson's disease disrupts the cargo sorting function of retromer | Q39072935 | ||
| Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD). | Q39333338 | ||
| Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing. | Q39562553 | ||
| Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. | Q34397099 | ||
| Transfer of human α-synuclein from the olfactory bulb to interconnected brain regions in mice | Q34909750 | ||
| LRRK2 localizes to endosomes and interacts with clathrin-light chains to limit Rac1 activation | Q35006939 | ||
| Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis | Q35058315 | ||
| VPS35 mutations in Parkinson disease | Q35103751 | ||
| Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers | Q35106295 | ||
| CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy | Q35122963 | ||
| Genetic LRRK2 models of Parkinson's disease: Dissecting the pathogenic pathway and exploring clinical applications | Q35148581 | ||
| The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? | Q35206992 | ||
| Hsc70 protein interaction with soluble and fibrillar alpha-synuclein | Q35266716 | ||
| LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice | Q35288337 | ||
| Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats | Q35313910 | ||
| Ubiquitin ligase Nedd4 promotes alpha-synuclein degradation by the endosomal-lysosomal pathway | Q35344983 | ||
| Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death | Q35484581 | ||
| VPS35 haploinsufficiency increases Alzheimer's disease neuropathology. | Q35670733 | ||
| Glucocerebrosidase depletion enhances cell-to-cell transmission of α-synuclein | Q35674483 | ||
| Axon degeneration in Parkinson's disease | Q35923102 | ||
| Exploring the link between glucocerebrosidase mutations and parkinsonism | Q35955350 | ||
| Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders | Q35960413 | ||
| Regulation of Physiologic Actions of LRRK2: Focus on Autophagy | Q35997636 | ||
| VPS35 regulates developing mouse hippocampal neuronal morphogenesis by promoting retrograde trafficking of BACE1 | Q36468331 | ||
| Mapping the Subcellular Distribution of α-Synuclein in Neurons using Genetically Encoded Probes for Correlated Light and Electron Microscopy: Implications for Parkinson's Disease Pathogenesis | Q37012885 | ||
| In vivo silencing of alpha-synuclein using naked siRNA | Q37033987 | ||
| Is Parkinson's disease a prion disorder? | Q37293178 | ||
| Striatal Mechanisms Underlying Movement, Reinforcement, and Punishment | Q37431197 | ||
| Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease. | Q37782115 | ||
| Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease | Q37789909 | ||
| α-Synuclein and dopamine at the crossroads of Parkinson's disease | Q37801701 | ||
| Modelling of Parkinson's disease in mice | Q37957494 | ||
| Autosomal recessive parkinsonism | Q37968072 | ||
| Alpha-synuclein: from secretion to dysfunction and death | Q38028819 | ||
| Parkinson's Disease and Parkinsonism: Neuropathology | Q38036232 | ||
| P433 | issue | 10 | |
| P921 | main subject | parkinsonian syndrome | Q1531991 |
| Parkinson's disease | Q11085 | ||
| P304 | page(s) | 1054-1064 | |
| P577 | publication date | 2015-10-01 | |
| P1433 | published in | Lancet Neurology | Q15755067 |
| P1476 | title | Insights from late-onset familial parkinsonism on the pathogenesis of idiopathic Parkinson's disease | |
| P478 | volume | 14 |
| Q99711175 | A Critical LRRK at the Synapse? The Neurobiological Function and Pathophysiological Dysfunction of LRRK2 |
| Q42315677 | A Human Neural Crest Stem Cell-Derived Dopaminergic Neuronal Model Recapitulates Biochemical Abnormalities in GBA1 Mutation Carriers. |
| Q58803163 | A new hypothesis for Parkinson's disease pathogenesis: GTPase-p38 MAPK signaling and autophagy as convergence points of etiology and genomics |
| Q58730704 | Altered dopamine release and monoamine transporters in Vps35 p.D620N knock-in mice |
| Q64782437 | Are we listening to everything the PARK genes are telling us? |
| Q36566963 | Associations of Matrix Metalloproteinase-9 and Tissue Inhibitory Factor-1 Polymorphisms With Parkinson Disease in Taiwan |
| Q33836737 | CpG and Non-CpG Methylation in Epigenetic Gene Regulation and Brain Function |
| Q64092745 | DL-3-n-butylphthalide therapy for Parkinson's disease: A randomized controlled trial |
| Q47817283 | Detecting pathway relationship in the context of human protein-protein interaction network and its application to Parkinson's disease. |
| Q47316774 | Differential Alterations in Metabolism and Proteolysis-Related Proteins in Human Parkinson's Disease Substantia Nigra |
| Q41117800 | Dopaminergic neurons differentiating from LRRK2 G2019S induced pluripotent stem cells show early neuritic branching defects |
| Q36382728 | Dysregulation of the causative genes for hereditary parkinsonism in the midbrain in Parkinson's disease |
| Q40294127 | Epidemiology and causes of Parkinson's disease |
| Q39151939 | Genetic Determinants of Parkinson's Disease: Can They Help to Stratify the Patients Based on the Underlying Molecular Defect? |
| Q47162391 | Identification of Ser465 as a novel PINK1 autophosphorylation site |
| Q42376543 | Identification of VPS35 p.D620N mutation-related Parkinson's disease in a Taiwanese family with successful bilateral subthalamic nucleus deep brain stimulation: a case report and literature review |
| Q58716364 | In silico drug screening by using genome-wide association study data repurposed dabrafenib, an anti-melanoma drug, for Parkinson's disease |
| Q42268862 | Initial elevations in glutamate and dopamine neurotransmission decline with age, as does exploratory behavior, in LRRK2 G2019S knock-in mice |
| Q96576033 | Kinase inhibition of G2019S-LRRK2 enhances autolysosome formation and function to reduce endogenous alpha-synuclein intracellular inclusions |
| Q37299382 | Metformin Prevents Dopaminergic Neuron Death in MPTP/P-Induced Mouse Model of Parkinson's Disease via Autophagy and Mitochondrial ROS Clearance |
| Q47642958 | Microglia Gone Rogue: Impacts on Psychiatric Disorders across the Lifespan |
| Q86173854 | Multitarget disease-modifying therapy in Parkinson's disease? |
| Q48184416 | Network and Pathway-Based Analyses of Genes Associated with Parkinson's Disease. |
| Q96219413 | Neuron-autonomous susceptibility to induced synuclein aggregation is exacerbated by endogenous Lrrk2 mutations and ameliorated by Lrrk2 genetic knock-out |
| Q64759312 | Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders |
| Q37265491 | Port-to-port delivery: Mobilization of toxic sphingolipids via extracellular vesicles |
| Q37274276 | Systematic analysis of genetic variants in Han Chinese patients with sporadic Parkinson's disease. |
Search more.